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Cardiovascular de Colombia, 681004 Floridablanca, ColombiaIn vivo tissue-speciﬁc genome editing at the desired loci is still a
challenge. Here, we report that AAV9-delivery of truncated
guide RNAs (gRNAs) and Cas9 under the control of a
computationally designed hepatocyte-speciﬁc promoter lead
to liver-speciﬁc and sequence-speciﬁc targeting in the mouse
factor IX (F9) gene. The efﬁciency of in vivo targeting was as-
sessed by T7E1 assays, site-speciﬁc Sanger sequencing, and
deep sequencing of on-target and putative off-target sites.
Though AAV9 transduction was apparent in multiple tissues
and organs, Cas9 expression was restricted mainly to the liver,
with only minimal or no expression in other non-hepatic tis-
sues. Consequently, the insertions and deletion (indel) fre-
quency was robust in the liver (up to 50%) in the desired target
loci of the F9 gene, with no evidence of targeting in other or-
gans or other putative off-target sites. This resulted in a sub-
stantial loss of FIX activity and the emergence of a bleeding
phenotype, consistent with hemophilia B. The in vivo efﬁcacy
of the truncated gRNA was as high as that of full-length
gRNA. Cas9 expression was transient in neonates, representing
an attractive “hit-and-run” paradigm. Our ﬁndings have
potentially broad implications for somatic gene targeting in
the liver using the CRISPR/Cas9 platform.Received 21 December 2015; accepted 21 February 2018;
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CRISPR RNA-guided nucleases (Cas9 nucleases) offer encouraging
prospects for efﬁcient genome editing. These molecules have recently
been used to target speciﬁc genomic loci in vitro and in vivo, leading
to site-speciﬁc alterations in the targeted genes.1–5 CRISPR/Cas9-
mediated gene editing triggers a DNA-sequence-speciﬁc double-
strand6 DNA break that stimulates gene repair by either non-homol-
ogous end joining (NHEJ) or homologous recombination (HR) in the
presence of a homologous DNA template. NHEJ can also result in the
insertion or deletion of nucleotides at the target locus, resulting in
frameshift or nonsense mutations leading to a loss-of-function
phenotype. Genome editing using CRISPR/Cas9 has been particularly
effective to generate transgenic animals containing speciﬁc mutations
in the desired target loci through the genetic modiﬁcation of embry-
onic stem cells (ESCs)7,8 or zygotes,9–12 with broad implications for
functional genomics studies. In addition, CRISPR/Cas9 has been
used to genetically modify clinically relevant cell types ex vivo,Mo
This is an open access article under the CC BY-NC-Nincluding T cells and hematopoietic stem cells,13,14 induced pluripo-
tent stem cells (iPSCs)15,16 and other adult stem cells.17 This impacts
the ﬁeld of regenerative medicine for the treatment of degenerative
diseases.18–20
In vivo genome editing in post-natal animals, however, has been more
challenging. In vivo delivery of CRISPR/Cas9 has been achieved using
either hydrodynamic delivery or viral transduction with either adeno-
viral or adeno-associated virus (AAV) vectors.2,21–26 However, in
some cases, the targeting efﬁciency in somatic cells was relatively
modest (<1%)23 and failed to yield a distinct phenotype. Alternatively,
in vivo selection was required to enrich for the gene-edited cells,27
limiting its application to only those genes that conferred a selective
growth and survival advantage in vivo (e.g., fumarylacetoacetate hy-
drolase [Fah]). In particular, this limited efﬁciency was compounded
by the limited packaging capacity of AAV vectors and the relatively
large size of the conventional codon-usage optimized Streptococcus
pyogenes Cas9 (4.2 kb), necessitating the use of smaller promoters
that were either relatively weak and/or not tissue speciﬁc.23 The use
of adenoviral vectors for in vivo editing using CRISPR/Cas9 hampers
ultimate clinical translation, given its known inﬂammatory properties
following systemic administration that often provoke liver toxicity
and rapid immune clearance of gene-modiﬁed cells.28 In addition,
most of the adenoviral vector-based genome editing studies used a
ubiquitously expressed cytomegalovirus (CMV) promoter to drive
the Cas9 protein, increasing the likelihood of undesired genome edit-
ing in non-target tissues. Finally, all of the previously published in vivo
editing studies relied on the use of non-truncated guide RNAs
(gRNAs), which are known to yield a higher frequency of non-speciﬁclecular Therapy Vol. 26 No 5 May 2018 ª 2018 The Author(s). 1241
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. AAV Copy Number in Liver, Lung, Heart, Kidney, Spleen, Brain,
Gastrocnemius Muscle, and Diaphragm
The AAV9-HS-CRM8-TTRmin-Cas9 vector (6.25  1010 vg/mouse i.v.) was co-
injected with either the AAV9-U6-mF9-Exon1-gRNA17, AAV9-U6-mF9-Exon6-
gRNA17, or control AAV9-U6-scrambled-gRNA vectors (1.25  1011 vg/mouse
i.v.). Vector copy number (mean ± SD) was determined by qPCR using primers
specific for the synthetic liver-specific HS-CRM8-TTRmin promoter driving Cas9
expression.
Molecular Therapyoff-target editing,29,30 as conﬁrmed following somatic in vivo edit-
ing.31 These limitations justify the development and validation of
robust tissue-speciﬁc in vivo gene editing platforms that further mini-
mize the risk of off-target gene editing in non-target genes and/or
non-target tissues. In this study, we address these limitations and vali-
dated an improved CRISPR/Cas9-based AAV platform32,33 capable of
achieving efﬁcient and stable liver-speciﬁc genome editing in vivo
with a potentially reduced risk of off-target effects in non-target genes
while also preventing gene targeting in non-target organs.
RESULTS
Selection of gRNA Target Sites and Design of the Liver-Specific
AAV9-Cas9 Vector
Truncated and full-length gRNAs were speciﬁcally designed to target
the murine factor IX (F9) gene using CRISPR/Cas9, taking into ac-
count the following considerations: (1) the target sites were selected
at the 50 end of the F9 gene, making it more likely to generate a
non-functional coagulation factor IX (FIX) protein by introducing
frameshift mutations following NHEJ;18 (2) the target sites overlap
with mutations known to cause hemophilia B in patients, based on
the human FIX database (http://www.factorix.org/); and (3) the
selected gRNAs were subjected to a genome-wide analysis using a
computational BLAST tool (Ensembl; NCBI) to ensure that the
cognate target sites are uniquely present in the mouse genome.
Truncated (i.e., mF9 Exon1 gRNA17 and mF9 Exon6 gRNA17) and
full-length (i.e., mF9 Exon1 gRNA20) gRNAs were selected34 based
on these criteria that were designed to target either exon 1 or exon1242 Molecular Therapy Vol. 26 No 5 May 20186 of the mouse F9 gene (Tables S1 and S2). All gRNAs were driven
by a polymerase III (U6) promoter and cloned into an AAV vector.
The corresponding AAV9-U6-mF9-Exon1-gRNA20 (full-length
gRNA), AAV9-U6-mF9-Exon1-gRNA17 (truncated gRNA), and
AAV9-U6-mF9-Exon6-gRNA17 (truncated gRNA) vectors were pro-
duced and yielded normal vector titer (9  1012–3  1013 vg/mL).
To selectively express Cas9 in the liver, we used a synthetic chimeric
liver-speciﬁc promoter (designated as HS-CRM8-TTRmin) that was
speciﬁcally designed to achieve high levels of hepatocyte-speciﬁc
expression with no or only minimal ectopic expression in non-target
tissues.35,36 This robust liver-speciﬁc promoter was composed of a
computationally designed hepatocyte-speciﬁc cis-regulatory module
(HS-CRM8) coupled to a minimal transthyretin (TTRmin) promoter.
One particularly attractive attribute of this HS-CRM8 element is its
small size (72 bp) and, in conjunction with the TTRmin (0.202 kb),
allows for a 5- to 10-fold increase in gene expression. Consequently,
this HS-CRM8-TTRmin promoter (0.27 kb) could be readily accom-
modated within a single-stranded (ss)AAV vector backbone to drive
expression of a relatively large transgene like Cas9 (4.2 kb). Typi-
cally, the titers of the corresponding AAV9-HS-CRM8-TTRmin-
Cas9 vectors fell within the range of 3  1012 to 1  1013 vg/mL.
We performed various experiments to achieve somatic gene inactiva-
tion of the mouse F9 gene. In the ﬁrst experiment, we injected 6.25
1010 vg/mouse of the AAV9-HS-CRM8-TTRmin-Cas9 vector intra-
venously (i.v.) in neonatal C57BL/6 mice in combination with either
the AAV9-U6-mF9-Exon1-gRNA17 or AAV9-U6-mF9-Exon6-
gRNA17 vector (1.25  1011 vg/mouse i.v.). Neonatal C57BL/6 mice
injected with AAV9-HS-CRM8-TTRmin-Cas9 and AAV9 encoding
a scrambled gRNA (i.e., AAV9-U6-scrambled-gRNA) were used as
controls. We next determined the biodistribution of the AAV9-HS-
CRM8-TTRmin-Cas9 vector. qPCR analysis using primers speciﬁc
for the synthetic HS-CRM8-TTRmin promoter revealed efﬁcient
transduction of the liver and, to a lesser extent, in other organs. In
particular, vector copy number was 10-fold higher (p < 0.05) in the
liver than in heart or brain. AAV copy numbers in skeletal muscle,
spleen, lung, and kidney were typically less than 1% (p < 0.001) of
what could be achieved in the liver (Figure 1). This biodistribution
is consistent with the known transduction pattern of AAV9.33,37
CRISPR-Cas9-Mediated Somatic Inactivation of FIX Results in a
Hemophilic Phenotype
In the ﬁrst experiment, co-injection of the AAV9-HS-CRM8-
TTRmin-Cas9 vector with either AAV9-U6-mF9-Exon1-gRNA17 or
AAV9-U6-mF9-Exon6-gRNA17 resulted in a signiﬁcant reduction
of FIX activity levels (Figures 2A and 2B; p < 0.01) compared to con-
trols injected with AAV9-HS-CRM8-TTRmin-Cas9 along with
AAV9-U6-scrambled-gRNA. Two different doses of AAV9-HS-
CRM8-TTRmin-Cas9 vector (i.e., 6.25  1010 vg/mouse or 1.25 
1011 vg/mouse i.v.) and AAV9-U6-mF9-Exon1-gRNA17, AAV9-
U6-mF9-Exon6-gRNA17 vector, or control AAV9-U6-scrambled-
gRNA (i.e., 1.25  1011 vg/mouse or 2.5  1011 vg/mouse i.v.) were
evaluated. Interestingly, the reduction of the FIX activity levels was
A B
C
Figure 2. FIX Activity Levels and Bleeding Time after Gene Targeting with
U6-mF9-Exon1-gRNA and U6-mF9-Exon6-gRNA
(A and B) For FIX activity levels (mean ± SD), two different doses of the AAV9-
HS-CRM8-TTRmin-Cas9 vector (i.e., A, 6.25  1010 vg/mouse or B, 1.25 
1011 vg/mouse i.v.) and AAV9-U6-mF9-Exon1- gRNA17, AAV9-U6-mF9-Exon6-
gRNA17, or control AAV9-U6-scrambled-gRNA (i.e., A, 1.25 1011 vg/mouse or B,
2.5  1011 vg/mouse i.v.) were evaluated. FIX activity was determined using a
functional FIX assay on mouse plasma obtained from the injected mice at distinct
time points post-vector-injection. (C) Bleeding time (mean ± SD) after gene targeting
with the AAV9-HS-CRM8-TTRmin-Cas9 vector (6.25  1010 vg/mouse i.v.) and
AAV9-U6-mF9-Exon1- gRNA17 or AAV9-U6-mF9-Exon6- gRNA17 vector or control
AAV9-U6-scrambled-gRNA (1.25  1011 vg/mouse i.v.) is shown. *p < 0.05
(Student’s t-test); ns, not significant (p > 0.1).
www.moleculartherapy.orgmore pronounced after gene targeting with U6-mF9-Exon1-gRNA17
(p < 0.01) than with mF9-Exon6-gRNA17 (Figures 2A and 2B)
and could not be increased further by increasing the AAV9-HS-
CRM8-TTRmin-Cas9 and AAV9-U6-mF9-Exon1-gRNA17 vector
doses. This suggests that saturation had been attained in the case of
this mF9-Exon1-gRNA17 targeting vector. However, increasing
the AAV9-HS-CRM8-TTRmin-Cas9 and AAV9-U6-mF9-Exon6-
gRNA17 vector doses resulted in a further reduction in FIX activity
levels until it was comparable to what could be attained with the
AAV9-U6-mF9-Exon1-gRNA17 vector. This suggests that the extent
of the reduction in FIX activity—and hence the targeting efﬁciency—
varies, depending on the intrinsic properties and/or target site of the
gRNA. Most importantly, the loss of FIX activity after in vivo liver-directed editing with CRISPR/Cas9 was consistent with the emer-
gence of a hemophilic phenotype (Figure 2C). In particular, co-
injection of AAV9-HS-CRM8-TTRmin-Cas9 vector with either
AAV9-U6-mF9-Exon1-gRNA17 or AAV9-U6-mF9-Exon6-gRNA17
in wild-type C57BL/6 mice resulted in a signiﬁcant prolongation in
bleeding time (p < 0.05). The effect on the bleeding diathesis was
even more pronounced after gene targeting with U6-mF9-Exon1-
gRNA17 than with mF9-Exon6-gRNA17 (Figure 2C), consistent
with the observed differences in FIX activity levels at these vector
doses (Figure 2A). Consequently, the FIX activity levels attained after
CRISPR/Cas9-mediated in vivo targeting of the mouse F9 gene corre-
lated with the severity of the bleeding phenotype.
The use of truncated gRNAs was justiﬁed based on a previous report,
demonstrating a decrease in off-target effects in transfected cell lines
in vitro compared to when full-length gRNAs were employed.34 Our
initial experiments indicated that the gRNA targeting exon 1 of mu-
rine F9 yielded the most robust decline in mFIX activity levels
compared to the gRNA targeting exon 6. This was consistent with
the highest frequency of insertions and deletions (indels) at this
site. To compare the relative efﬁciency and speciﬁcity of truncated
versus full-length gRNAs, we therefore designed AAV9 vectors ex-
pressing gRNAs that contain either 17 nt (truncated, designated as
AAV9-U6-mF9-Exon1-gRNA17) or 20 nt (full-length, designated as
AAV9-U6-mF9-Exon1-gRNA20) that are complementary to the
same target sequence in exon 1 of the mouse F9 gene (Figures 3A
and 3B).
The AAV9-U6-mF9-Exon1-gRNAs encoding either the full-length
20 nt or truncated 17 nt gRNAs were co-injected with AAV9-HS-
CRM8-TTRmin-Cas9 vector into either neonates (n = 6 per cohort;
dose: 6.25  1010 vg/mouse of the AAV9-HS-CRM8-TTRmin-Cas9
and 1.25  1011 vg/mouse of AAV9-U6-mF9-Exon1-gRNA17 or
AAV9-U6-mF9-Exon1-gRNA20 vector or AAV9-U6-scrambled-
gRNA) or 4-week-old C57BL/6 mice (n = 3 per cohort; dose:
1.25  1011 vg/mouse of the AAV9-HS-CRM8-TTRmin-Cas9 and
2.50  1011 vg/mouse of AAV9-U6-mF9-Exon1-gRNA17 or AAV9-
U6-mF9-Exon1-gRNA20 vector or AAV9-U6-scrambled-gRNA).
Both full-length and truncated gRNAs reduced mFIX activity by
approximately 50% (Figure 3C). The decline in FIX expression was
sustained over 1 year after vector injection (data not shown). Simi-
larly, the 4-week-old C57BL/6 mice with the CRISPR/Cas9 vectors,
both the full-length and truncated gRNA, resulted in a signiﬁcant
reduction in FIX activity compared to PBS control or scrambled
gRNA. There was no signiﬁcant difference (p = 0.11) in targeting ef-
ﬁciency when comparing the 20 nt with the 17 nt gRNA (Figure 3D).
The reduction in FIX activity was relatively stable over time, indicating
that long-term expression of Cas9 did not further enhance targeting ef-
ﬁciency (Figures 2A and 3C). We then tested the kinetics of Cas9 gene
expression and gene copy number to assess whether Cas9 expression
was sustained. This experiment was performed in C57BL/6 neonates
where 6.25  1010 vg/mouse of the AAV9-HS-CRM8-TTRmin-Cas9




Figure 3. The gRNA Structures and FIX Activity
Levels after Gene Targeting with U6-mF9-Exon1-
gRNA17 and U6-mF9-Exon1-gRNA20 in Neonatal
and 4-Week-Old Mice
(A and B) The detailed structure of the full-length 20-nt
(exon1 gRNA20) (A) and truncated 17-nt (exon1 gRNA17)
(B) gRNAs, respectively. (C) For FIX activity levels (mean ±
SD) in neonates, the AAV9-HS-CRM8-TTRmin-Cas9
vector (6.25  1010 vg/mouse i.v.) and AAV9-U6-mF9-
Exon1-gRNA17, AAV9-U6-mF9-Exon1-gRNA20, or con-
trol AAV9-U6-scrambled-gRNA (1.25  1011 vg/mouse
i.v.) were evaluated. PBS-injected neonates were also
used as control group. FIX activity was determined using
a functional FIX assay on mouse plasma obtained from
the injected mice at distinct time points post-vector-in-
jection. (D) For FIX activity levels (mean ± SD) in 4-week-
old mice, the AAV9-HS-CRM8-TTRmin-Cas9 vector
(i.e.,1.25  1011 vg/mouse i.v.) and AAV9-U6-mF9-
Exon1-gRNA17, AAV9-U6-mF9-Exon1-gRNA20, or con-
trol AAV9-U6-scrambled-gRNA (2.5  1011 vg/mouse
i.v.) were evaluated. PBS-injected neonates were also
used as control group. FIX activity was determined using
a functional FIX assay on mouse plasma obtained from
the injected mice at distinct time points post-vector-
injection.
Molecular Therapy(exon 1 gRNA20) was administered. The results showed that there is a
signiﬁcant reduction (p < 0.05) in the Cas9 copy number and mRNA
expression over time (Figures 4A and 4B). This indicates that liver-spe-
ciﬁc expression ofCas9 is transient afterAAV transduction inneonates.
This represents an attractive “hit-and-go” scenario to maximize Cas9
expression and gene targeting during a critical window while prevent-
ing long-term expression of high levels of Cas9 protein. In addition, he-
patic delivery and Cas9 expression, in either neonates or adults, may
have contributed to immune tolerance to Cas9. This is consistent
with previous reports demonstrating the potential of liver-directed
gene therapy for immune tolerance induction, regardless of the vector
used, in either neonates or adults.38–40
We conducted 3 independent experiments to determine both aspar-
tate aminotransferase (AST) and alanine aminotransferase (ALT)
levels in order to obtain comprehensive serum biochemistry. Two-
day-old C57BL/6 neonates were injected with 6.25  1010 vg/mouse1244 Molecular Therapy Vol. 26 No 5 May 2018of the AAV9-HS-CRM8-TTRmin-Cas9 and
1.25  1011 vg/mouse of the respective AAV9-
U6-mF9-gRNA vectors (Figures S1A and
S1B), which was repeated with an indepen-
dently produced vector batch (Figures S1C
and S1D). Alternatively, 4-week-old C57BL/6
mice were injected with 1.25  1011 vg/mouse
of the AAV9-HS-CRM8-TTRmin-Cas9 and
2.50  1011 vg/mouse of the respective AAV9-
U6-mF9-gRNA vectors (Figures S1E and S1F).
There was no signiﬁcant elevation in AST and
ALT levels, consistent with the lack of chronicliver inﬂammation or hepatotoxicity (Figure S1). In addition, we
have tested for the presence anti-Cas9 antibodies in the plasma sam-
ples using a Cas9-speciﬁc ELISA at various time points. For all con-
ditions, the levels of these antibodies were similar to the PBS-injected
or scrambled-injected controls. This indicates there is no develop-
ment of anti-Cas9 antibodies (Figure S2A). We have also conducted
a comprehensive cytokine ELISA on plasma samples, testing for the
presence of interleukin-1b (IL-1-b), IL-2, IL-6, IL-10, IL-12, inter-
feron g (IFN-g), and tumor necrosis factor alpha (TNF-a). None
of these cytokines were induced in the plasma of recipient mice
4 weeks after injection, consistent with the lack of any immune
response against Cas9 (Figure S2B).
This further supports the notion that targeting the endogenous F9
locus using either the AAV9-U6-mF9-Exon1-gRNA or AAV9-U6-
mF9-Exon6-gRNA targeting constructs yielded no untoward hepato-
toxicity or liver inﬂammation.
AB
Figure 4. Cas9 Kinetic Analysis by Measuring mRNA Expression and
Genomic DNA Copy Number in Liver, Heart, and Kidney
The AAV9-HS-CRM8-TTRmin-Cas9 vector (6.25  1010 vg/mouse i.v.) was co-
injected with the AAV9-U6-mF9-Exon1-gRNA20 (1.25  1011 vg/mouse i.v.), and
the mRNA and genomic DNA expression was measured at day 9 and day 90 post-
injection. (A) Cas9 mRNA expression (mean ± SD) was determined by qRT-PCR
using primers specific for Cas9. Normalization was carried out using mouse
GAPDH-specific primers. Cas9 expression was presented in terms of 2-DCT values.
(B) Vector copy number (mean ± SD) was determined by qPCR using primers
specific for the synthetic liver-specific HS-CRM8-TTRmin promoter driving Cas9
expression.
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Enzyme Mismatch Cleavage Method
To assess the targeting efﬁciency at the respective target sites in the
mouse F9 gene, we explored the use of an enzyme mismatch cleavage
method based on the bacteriophage resolvase T7E1. The T7E1-based
enzyme mismatch cleavage method assay takes advantage of the abil-
ity of T7E1 to cleave heteroduplex DNA at mismatches formed by
single or multiple nucleotides. In contrast, cleavage activity of T7E1
is greater on mismatched than on Watson-Crick base pairs, though
homoduplex DNA can be cleaved to a certain extent.41,42 Hence,
T7E1 is well suited to discriminate between homoduplex and hetero-
duplex double-stranded DNA (dsDNA). T7E1 analysis revealed that
co-injection of the AAV9-HS-CRM8-TTRmin-Cas9 vector (6.25 1010 vg/mouse i.v.) with either AAV9-U6-mF9-Exon1-gRNA17 or
AAV9-U6-mF9-Exon6-gRNA17 (1.25  1011 vg/mouse i.v.) resulted
in a signiﬁcant degree of heteroduplex dsDNA formation in the liver,
consistent with the introduction of indels by NHEJ repair at the
respective target loci in the mouse F9 gene (designated as % indels
in Figure 5 and Table 1). In particular, the extent of F9 gene targeting
in the liver was more pronounced after gene targeting with U6-
mF9-Exon1-gRNA17 (% indels: 42 ± 10) than with mF9-Exon6-
gRNA17 (% indels: 26 ± 21; Figure 5). This difference in targeting
efﬁciency at the respective F9 loci based on the two distinct gRNAs
correlated with the differences in reduction of FIX activity (Figure 2A)
and differences in prolongation of bleeding time (Figure 2C). In
contrast, control mice injected with AAV9-HS-CRM8-TTRmin-
Cas9 vector (6.25  1010 vg/mouse i.v.) with AAV9-U6-scrambled-
gRNA (1.25 1011 vg/mouse i.v.) failed to yield any evidence of liver
targeting in the F9 gene based on the T7E1 assay, consistent with the
lack of heteroduplex formation at the target locus (Figures 5A and 5C;
lanes 9–11). Similarly, control mice not injected with any Cas9 or
gRNA vectors did not exhibit any targeting based on the T7E1 assay
(Figures 5A and 5C; lanes 1 and 2).
Indeed, there was no evidence of heteroduplex formation based on the
T7E1 assay in heart or lungs of mice injected with AAV9-HS-CRM8-
TTRmin-Cas9 and AAV9-U6-mF9-Exon1-gRNA17 or AAV9-U6-
mF9-Exon6-gRNA17 (Table 1; Figures S5A–S5C).
Sequencing Analysis of On-Target and Off-Target Gene Editing
To independently conﬁrm that the heteroduplexes detected using the
T7E1-based enzyme mismatch cleavage method following in vivo
CRIPSR/Cas9 gene delivery contained indels at the respective target
sites in the F9 locus, we performed sequencing analysis. Sanger
sequencing of cloned PCR products derived from liver tissue revealed
the presence of indels at the respective loci. In AAV9-HS-CRM8-
TTRmin-Cas9 vector and AAV9-U6-mF9-Exon1-gRNA17 co-in-
jected mice, 4 out of 18 sequenced clones (22%) showed evidence
of deletion and 3 out of 18 clones (17%) showed presence of insertions
at the target site. In total, 7 out of 18 clones (39%) demonstrated the
presence of indels (Figure S3). In AAV9-HS-CRM8-TTRmin-Cas9
vector and AAV9-U6-mF9-Exon6-gRNA17 co-injected mice, 6 out
of 19 sequenced samples showed evidence of deletion (5 small dele-
tions and 1 large deletion; 32%) at the target site of mF9-Exon6
gRNA (Figure S3). These indels are consistent with the mechanism
of action of CRISPR/Cas9-mediated gene editing, resulting in dsDNA
breaks followed by NHEJ.4,34 In contrast, PCR products obtained
from control mice injected with AAV9-HS-CRM8-TTRmin-Cas9
vector (6.25  1010 vg/mouse i.v.) with AAV9-U6-scrambled-
gRNA (1.25  1011 vg/mouse i.v.) did not show any evidence of
indels.
Subsequently, a more comprehensive sequencing analysis was per-
formed on the respective target loci in the F9 gene. In particular,
deep sequencing was ﬁrst performed on the PCR products obtained
from liver after in vivo CRISPR/Cas9 delivery. In mice co-injected
with the AAV9-HS-CRM8-TTRmin-Cas9 (6.25  1010 vg/mouseMolecular Therapy Vol. 26 No 5 May 2018 1245
Figure 5. Assessment of AAV9-U6-mF9-Exon1-
gRNA17- and AAV9-U6-mF9-Exon6-gRNA17-
Induced Indels in Liver Genomic DNA Based on the
T7E1-Based Enzyme Mismatch Cleavage Assay
(A) T7E1 digestion of PCR products at the mF9-
Exon1-gRNA target site. Exon1 corresponds to mice
injected with AAV9-U6-mF9-Exon1-gRNA17 (1.25 
1011 vg/mouse i.v.), scrambled corresponds to AAV9-U6-
scrambled-gRNA-injected mice (1.25  1011 vg/mouse
i.v.), and Cas9 corresponds to AAV9-HS-CRM8-TTRmin-
Cas9-injected mice (6.25  1010 vg/mouse i.v.). (B)
Densitometric quantification of bands in gel images of (A)
to determine gene targeting efficiency is shown. Sample
specifications: 1 and 2, wild-type C57BL/6 mice (no guide
RNA or Cas9 vectors injected); 3, 4, and 5, mice
co-injected with AAV9-HS-CRM8-TTRmin-Cas9 and
AAV9-U6-mF9-Exon1-gRNA17; 9, 10, and 11, control
mice co-injected with AAV9-HS-CRM8-TTRmin-Cas9
and AAV9-U6-scrambled-gRNA. M is the molecular
weight ladder. (C) T7E1 digestion of PCR products at the
mF9-Exon6-gRNA target site is shown. Exon6 corre-
sponds to mice injected with AAV9-U6-mF9-Exon6-
gRNA17 (1.25  1011 vg/mouse i.v.), scrambled corre-
sponds to AAV9-U6-scrambled-gRNA-injected mice
(1.25  1011 vg/mouse i.v.), and Cas9 corresponds to
AAV9-HS-CRM8-TTRmin-Cas9-injected mice (6.25 
1010 vg/mouse i.v.). (D) Densitometric quantification of
bands in gel images of (C) to determine gene targeting
efficiency is shown. Sample specifications: 1 and 2, wild-
type C57BL/6 mice (no guide RNA or Cas9 vectors in-
jected); 6, 7, and 8, mice co-injected with AAV9-HS-
CRM8-TTRmin-Cas9 and AAV9-U6-mF9-Exon6-gRNA17
injected; 9, 10, and 11, control mice co-injected with
AAV9-HS-CRM8-TTRmin-Cas9 and AAV9-U6-scram-
bled-gRNA. M is the molecular weight ladder. (E) Com-
posite figure illustrating the percentage of indels (mean ±
SD) assessed by T7E1-based enzyme mismatch cleav-
age assay and deep sequencing for both AAV9-U6-mF9-
Exon1-gRNA17 and AAV9-U6-mF9-Exon6-gRNA17.
Molecular Therapyi.v.) and AAV9-U6-mF9-Exon1-gRNA17 vectors (1.25 
1011 vg/mouse i.v.), up to 56% sequence reads (based on a total of
655,818 reads) showed indels at the corresponding target site in
exon 1 of the F9 gene (Table 2; Figure S4A). Similarly, in mice co-in-
jected with the AAV9-HS-CRM8-TTRmin-Cas9 vector (6.25 
1010 vg/mouse i.v.) and AAV9-U6-mF9-Exon6-gRNA17, up to 19%
sequence reads (based on a total of 588,158 reads) showed indels at
the corresponding target site in exon 6 of the F9 gene. This suggests
that targeting with the exon-1-speciﬁc gRNA was more efﬁcient
than with the exon-6-speciﬁc gRNA (Table 2; Figure S4B). This is
consistent with the differences in heteroduplex formation based on
the T7E1-based enzyme mismatch cleavage assay (Figure 5; Table 1),
the differences in the extent of the reduction in FIX activity (Figures
2A and 2B), and the prolongation of bleeding time (Figure 2C). In
contrast, control mice co-injected with AAV9-HS-CRM8-TTRmin-
Cas9 (6.25  1010 vg/mouse i.v.) and AAV9-U6-scrambled-gRNA
(1.25 1011 vg/mouse i.v.) failed to show any indels in these F9 target
loci. This is consistent with the T7E1 data (Figure 5) and reﬂects the1246 Molecular Therapy Vol. 26 No 5 May 2018hepatocyte speciﬁcity of the HS-CRM8-TTRmin promoter used
to drive Cas9 expression (Table 1). Finally, on examining the
deep sequencing data for putative top three off-target sites (Table
S2) in liver genomic DNA of mice co-injected with AAV9-HS-
CRM8-TTRmin-Cas9 vector (6.25  1010 vg/mouse i.v.) and either
AAV9-U6-mF9-Exon1-gRNA17 or AAV9-U6-mF9-Exon6-gRNA17,
no evidence for indels was visible (Table 2). This conﬁrms the on-
target speciﬁcity of the CRISPR/Cas9 system after in vivo gene delivery,
which may be due to, at least in part, by the use of truncated gRNA.
In our next experiment comparing the full-length and truncated
gRNA, the AAV9-U6-mF9-Exon1-gRNAs encoding either the full-
length 20 nt or truncated 17 nt gRNAs were co-injected with
AAV9-HS-CRM8-TTRmin-Cas9 vector into either neonates (n = 6
per cohort; dose: 6.25  1010 vg/mouse of the AAV9-HS-CRM8-
TTRmin-Cas9 and 1.25  1011 vg/mouse of AAV9-U6-
mF9-Exon1-gRNA17 or AAV9-U6-mF9-Exon1-gRNA20 vector or
AAV9-U6-scrambled-gRNA). Both full-length and truncated gRNAs
Table 1. Frequencies of Guide RNAs Induced Indel Mutations at On-Target Sites in Mice Tissues as Determined by T7E1 Assay
gRNA ID Injected Target ID Gene Genomic DNA gRNA Target (17 nt) (50–30) Mean % Indels ± SDa
Exon 1 Exon1-gRNA17 F9 liver GCACCTGAACACCGTCATGG 42 ± 10
Exon 1 Exon1-gRNA17 F9 heart GCACCTGAACACCGTCATGG not detected
Exon 1 Exon1-gRNA17 F9 lung GCACCTGAACACCGTCATGG not detected
Exon 6 Exon6-gRNA17 F9 liver GACTTCACTCGAGTTGTTGG 26 ± 21
Exon 6 Exon6-gRNA17 F9 heart GACTTCACTCGAGTTGTTGG not detected
Exon 6 Exon6-gRNA17 F9 lung GACTTCACTCGAGTTGTTGG not detected
aMutation frequencies were assessed based on the T7E1 assay with means of triplicate measurements
www.moleculartherapy.orgreduced mFIX activity by approximately 50% (Figure 3C). This was
independently conﬁrmed by deep sequencing (Table 3). There was
no signiﬁcant difference in percentage indels obtained with the full-
length or truncated gRNA at the target site in exon 1 of murine F9,
consistent with the deep sequencing and mFIX expression data.
The decline in FIX expression was sustained over 1 year after vector
injection (data not shown).
DISCUSSION
In this study, we have validated and improved a CRISPR/Cas9-based
AAV platform to achieve efﬁcient and stable liver-speciﬁc gene tar-
geting in vivo with a possible reduced risk of off-target effects in
non-target genes and/or non-target tissues or organs. One of its key
features is the incorporation of a computationally designed hepato-
cyte-speciﬁc synthetic promoter (designated as HS-CRM8-TTRmin
promoter) to speciﬁcally direct high Cas9 expression levels in the
liver. This promoter contains a 72-bp hepatocyte-speciﬁc cis-regula-
tory module (i.e., HS-CRM8) that is composed of a cluster of tran-
scription factor binding site (TFBS) motifs characteristic of highly
expressed liver-speciﬁc genes.35,36 Most importantly, by virtue of its
small size, this synthetic de novo-designed promoter allows for the
incorporation of the Streptococcus pyogenes Cas9 (4.2 kb) within
an AAV backbone without compromising efﬁcacy. The use of this
small but potent synthetic promoter thereby overcomes some of the
limitations that precluded the use of S. pyogenes Cas9 in AAV vectors,
given its intrinsic packaging constraints. To assess the robustness of
this approach, we estimated the efﬁcacy of gene inactivation in vivo
using coagulation F9 as the target gene, and, as a proof of concept,
we observed the bleeding phenotype consistent with hemophilia B.
In vivo gene delivery of CRISPR/Cas9 using these hepatocyte-speciﬁc
AAV did not provoke any hepatotoxicity, suggesting that it is a
relatively safe approach for in vivo gene editing, supporting its use
for potential clinical applications.
The targeting efﬁciency and speciﬁcity obtained with the current
AAV-based approach compares favorably with that obtained using
other strategies. In particular, in vivo delivery of CRISPR/Cas9 by
hydrodynamic delivery resulted in relatively modest targeting efﬁ-
ciency,27 necessitating in vivo selection of the gene-edited cells.23
Our current approach is more efﬁcient, obviating the need for such
in vivo selection schemes to enrich for gene-editing cells. Althoughthe use of hydrodynamic injection method can be beneﬁcial for the
generation of mouse models, this method is not well suited for human
clinical applications, given the transient ﬂuid overload and its impact
on cardiac function.43 Previous somatic in vivo gene delivery studies
using AAV-based vectors expressing S. pyogenes Cas9 also resulted in
relatively modest gene editing efﬁciencies, which were insufﬁcient to
yield a robust phenotype,23 in contrast to our present study. This was
likely due to, at least in part, the use of smaller promoters that were
either relatively weak and/or not tissue speciﬁc.23 The targeting efﬁ-
ciencies obtained with the current hepatocyte-speciﬁc AAV-based
approach were comparable to the levels obtained with adenoviral vec-
tors.21 However, adenoviral vectors are known to provoke signiﬁcant
inﬂammatory responses following systemic administration28,32 that
can trigger liver toxicity, in contrast to when AAV vectors were em-
ployed.35 This is compounded by the possible immune-adjuvant ef-
fect that may increase the risk of developing an immune response
against the Cas9 protein and/or the Cas9-expressing cells.20 More-
over, because most adenoviral vectors expressed Cas9 from a ubiqui-
tously expressed CMV promoter, and because they exhibit a broad
cellular tropism, this increases the risk of unwanted gene editing in
non-target tissues.
Typically, therapeutic applications based on CRISPR/Cas9 rely on its
ability to induce a dsDNA break in a DNA-sequence-speciﬁc manner,
as determined by the gRNA sequence. In the absence of a homologous
DNA donor template, this dsDNA break is repaired by NHEJ. This
could result either in gene inactivation or gene repair, potentially
restoring expression of a functional protein. If a homologous DNA
donor template is provided, it can prompt homology-directed repair
(HDR) at the dsDNA break, allowing replacement of the mutated
with a corrected gene sequence. The ability to edit genes by either
NHEJ or HDR critically depends on the efﬁciency of dsDNA cleavage
at the desired locus. Our present study therefore focuses on this crit-
ical step in the gene editing process and shows that AAV-mediated
delivery using de novo-designed liver-speciﬁc promoters allows for
efﬁcient liver-speciﬁc gene targeting, without any detectable off-target
effects or adverse immune consequences, consistent with lack of
anti-Cas9 antibodies or cytokine elevations. This paves the way
toward future therapeutic liver-directed gene editing applications.
Moreover, it also validates the current optimized system for animal
modeling based on efﬁcient and speciﬁc somatic liver-directed geneMolecular Therapy Vol. 26 No 5 May 2018 1247
Table 2. Frequencies of Guide RNAs Induced Indel Mutations at On- and Off-Target Sites in Mice Tissues as Determined by Deep Sequencing
gRNA ID Injected Target ID Gene Genomic DNA gRNA Target (17 nt) (50–30) % of Reads Supporting an Indel
Exon 1 Exon1-gRNA17 F9 liver GCACCTGAACACCGTCATGG 56
Exon 1 Exon1-OT1 – liver GCACATGAACAGCGTCAGAG not detected
Exon 1 Exon1-OT2 – liver GACCCTGAACACCCTCATGG not detected
Exon 1 Exon1-OT3 – liver GTACCTGAACACCTTCTGAG not detected
Exon 6 Exon6-gRNA17 F9 liver GACTTCACTCGAGTTGTTGG 19
Exon 6 Exon6-OT1 Grin2b liver CACTTCACTCGAGTTGGGGG not detected
Exon 6 Exon6-OT2 – liver CACTTCACTAGAGTTGTTAG not detected
Exon 6 Exon6-OT3 – liver TACTACACTGGAGTTGTTGG not detected
Molecular Therapyinactivation. AAVs have recently been used for hepatic delivery of
designer nucleases (i.e., zinc ﬁnger nucleases [ZFNs]) in patients
suffering from a hereditary disease (i.e., Hunter syndrome).44
Depending on the outcome of this trial, it is conceivable that the
AAV platform may also be used in the future for hepatic delivery
and expression of CRISPR/Cas9 components. Restricting expression
of Cas9 in hepatocytes and obtaining sufﬁciently high levels to
“maximize” gene targeting, as shown in the present study, is an
important step toward achieving that goal.
AAVs offer many advantages over adenoviral vectors for clinical
translation and animal modeling. Adenoviral delivery of CRISPR/
Cas9 components resulted in inadvertent immune responses, such
as Cas9-speciﬁc antibodies.7 It is also known that adenoviral vectors,
even helper-dependent vectors, can trigger T-cell-mediated clearance
of gene-modiﬁed cells, including hepatocytes.45 Consequently, these
confounding immune variables may interfere with the interpretation
of the consequences of CRISPR/Cas9 effects in mouse models. More-
over, it is well established that systemic administration of adenoviral
vectors results in efﬁcient transduction of innate immune effectors
and consequently carries a substantial risk of liver inﬂammation, re-
sulting in lethal consequences in trial subjects.46 These disadvantages
have severely hampered clinical applications based on adenoviral
vectors. Furthermore, AAV-mediated CRISPR/Cas9-mediated tar-
geting overcomes the intrinsic limitations of hydrodynamic delivery
methods that were used to deliver the CRISPR/Cas9 components to
the liver.27
Our current AAV-based study shows that the overall efﬁciency of
CRISPR/Cas9-mediated gene targeting is far greater than what has
been reported based on hydrodynamic CRISPR/Cas9 gene delivery
that typically results in liver toxicity, excess ﬂuid overload, and
cardiac insufﬁciency. Consequently, relatively modest targeting
efﬁciencies were obtained in the FIX gene by hydrodynamic gene
delivery of the CRISPR/Cas components.47–49
In particular, recently, Guan and colleagues47 showed that a F9 mu-
tation could be corrected in vivo by hydrodynamic tail vein injection
of a plasmid encoding Cas9 and the single-guide RNA (sgRNA) along
with either single-stranded oligodeoxynucleotide (ssODN; 120 nt) or1248 Molecular Therapy Vol. 26 No 5 May 2018long-donor DNA (with homology arms of 0.4 kb) containing the cor-
rected sequence. A therapeutic effect could be obtained using both
DNA donors, resulting in up to 0.56% and 1.5% of hepatocytes dis-
playing a corrected genotype using ssODNs and the long DNA,
respectively. A higher proportion of indels without correction was
apparent, indicating DNA cleavage with NHEJ repair and without
insertion of the donor DNA. Co-delivery of an adenoviral vector en-
coding Cas9 and a second one the sgRNA and the long DNA donor
resulted in a high frequency of hepatocyte correction (5.5%), at least
at early time points. However, no long-term correction of hemostasis
was observed, which could mostly likely be due to the high inﬂamma-
tion in the liver and hepatocyte death provoked by the adenoviral vec-
tors themselves.
The use of the hepatocyte-speciﬁc AAV-based CRISPR/Cas9 plat-
form described in the present study therefore provides an attractive
alternative that overcomes these limitations. Ultimately, the use of
AAVs may also be preferred for ultimate clinical applications, given
its attractive safety proﬁle.50 The current study provides a robust
alternative to the use of smaller-sized Cas9 variants for AAV
delivery.22 However, these Cas9 variants were not yet tested in vivo
in combination with the truncated gRNAs with higher speciﬁcity.
Some studies suggest that SaCas9 seems to work with similar efﬁ-
ciency to SpCas9, at least in vitro, and that the extent of off-target ef-
fects is comparable (ibid.),51 though this may vary depending on the
gRNA,52 requiring comprehensive head-to-head comparative studies.
However, one of the advantages of SaCas9 is its smaller size of 3.3 kb.
This enables the incorporation of both the Cas9 and gRNA expression
cassettes in a single AAV vector. It is encouraging that SaCas9 has
been used to achieve relatively efﬁcient gene targeting in the F9
gene, resulting in a therapeutic effect in hemophilic mice.53
However, there are also a number of limitations associated with the
use of SaCas9, which justiﬁes the exploration of SpCas9-based appli-
cations in parallel, for in vivo somatic gene inactivation. First, second-
generation, high-ﬁdelity SpCas9 derivatives (designated as SpCas9-
HF1) have been developed that harbor alterations designed to reduce
non-speciﬁc DNA contacts.54 SpCas9-HF1 retains on-target activities
comparable to wild-type SpCas9 but rendered all or nearly all
Table 3. Frequencies of Guide RNAs Induced Indel Mutations at On- and Off-Target Sites in Mice Tissues as Determined by Deep Sequencing Comparing
Truncated (17 nt) and Full-Length (20 nt) gRNAs
gRNA ID Injected Target ID Gene Genomic DNA gRNA Target (17 nt and 20 nt) (50–30) % of Reads Supporting an Indela
Exon 1 Exon1 gRNA17 F9 liver GCACCTGAACACCGTCATGG 34.98
Exon 1 Exon1-OT1 – liver GCACATGAACAGCGTCAGAG 0.01–0.1
Exon 1 Exon1-OT2 – liver GACCCTGAACACCCTCATGG 0.01–0.1
Exon 1 Exon1-OT3 – liver GTACCTGAACACCTTCTGAG 0.01–0.1
Exon 1 Exon1 gRNA20 F9 liver GAAGCACCTGAACACCGTCATGG 40.10
Exon 1 Exon1-OT1 – liver GCACATGAACAGCGTCAGAG 0.01–0.1
Exon 1 Exon1-OT2 – liver GACCCTGAACACCCTCATGG 0.01–0.1
Exon 1 Exon1-OT3 – liver GTACCTGAACACCTTCTGAG 0.01–0.1
aThe control liver samples obtained by injecting scrambled gRNA were also sequenced for the OT1/OT2/OT3 and resulted in no signiﬁcant indel reads (0.01%0.1%).
www.moleculartherapy.orgoff-target events undetectable by genome-wide break capture and tar-
geted sequencing methods. Hence, this SpCas9 derivative is consid-
ered one of the most precise Cas9 versions available to date and
can readily be accommodated in our liver-speciﬁc AAV vector con-
taining the computationally designed hepatocyte-speciﬁc promoter.
Second, the available SpCas9 sites (i.e., NGG) are more frequent in
the genome than for SaCas9 (i.e., NNGRRT), providing more oppor-
tunities to identify speciﬁc Cas9 cleavage sites for gene inactivation
or to facilitate HDR. Moreover, the commonly used SpCas9 can be
modiﬁed to recognize alternative PAM sequences beyond the proto-
typical NGG consensus.55 In particular, other SpCas9 variants were
generated that exhibit improved speciﬁcity in human cells, possessing
better discrimination against off-target sites with non-canonicalNAG
and NGA PAMs and/or mismatched spacers (ibid.). Third, the afore-
mentioned Ran et al.22 study did not include a head-to-head compar-
ative analysis of SaCas9 versus SpCas9 targeting efﬁciency and spec-
iﬁcity in vivo. Moreover, in some cases, only 5% indels could be
detected following in vivo liver-directed targeting with the all-in-
one SaCas9 vector.22 This justiﬁes the need for further comprehensive
comparative in vivo analyses of hepatic targeting with SaCas9 versus
SpCas9 and its derivatives.
Consequently, somatic gene inactivation with SpCas9 and its deriva-
tives has its merits and can be considered a valuable alternative to
SaCa9-based applications. In our current study, the novelty is based
primarily on the use of a small yet robust computationally designed
hepatocyte-speciﬁc synthetic promoter to drive Cas9 in an AAV vec-
tor. Moreover, to our knowledge, this is the ﬁrst in vivo study
comparing the efﬁciency and speciﬁcity of truncated gRNA for in vivo
SpCas9-mediated targeting. This allowed us to achieve relatively efﬁ-
cient somatic in vivo hepatic targeting, resulting in a distinctive hemo-
philic phenotype with no detectable off-target effects and with speciﬁc
targeting effects in the liver only. The current platform is therefore
well suited to express SpCas9 and its next-generation variants with
higher ﬁdelity and/or altered PAM speciﬁcities. In search of smaller
Cas9 enzymes for efﬁcient in vivo delivery by AAVs, short Cas9s
were also identiﬁed from the CRISPR1 locus of Streptococcus thermo-
philus LMD-9 (St1Cas9; 3.3 kb)1 as well as a rationally designedtruncated form of SpCas9.56 However, both systems have important
practical drawbacks: the former requires a complex PAM sequence
(NNAGAAW),57 which restricts the range of accessible targets,
whereas the latter exhibits signiﬁcantly reduced activity. Hence,
the performance of smaller Cas9 variants is not necessarily better
compared to the original SpCas9 or its next-generation derivatives.
All of the previously published in vivo somatic CRISPR/Cas9 editing
studies relied on the use of non-truncated gRNAs, which are known
to yield a higher frequency of non-speciﬁc off-target editing in vitro
and in vivo.29,31,34 In contrast, our current strategy relies on the use
of truncated gRNAs,whichwere previously shown to improve the spec-
iﬁcity of Cas9 targeting to the desired genomic locus and reduce off-
target editing, though based largely on in vitro studies in cell lines.34
The present study now extends the use of these truncated gRNAs with
increased targeting speciﬁcity for in vivo applications. We have con-
ducted an in vivo comparison of the full-length (20 nt) and truncated
(17 nt) gRNAs targeting Exon1 of murine F9 in both neonates and
4-week-old mice, which had not been done previously. This compre-
hensive in vivo analysis revealed that both the full-length and trun-
cated gRNAs signiﬁcantly reduced mFIX activity compared to the
control groups. This indicates that, for this locus, the full-length
and truncated gRNAs yielded comparable gene targeting efﬁciencies
as conﬁrmed by FIX levels and percentage of sequence reads support-
ing indels. Hence, it is encouraging that truncated gRNAs are at least
as efﬁcient as full-length gRNAs.
Using a previously developed computational algorithm, we identiﬁed
several putative off-target sites.30 We then assessed the frequency of
reads supporting indels at the top 3 ranked putative off-target sites
by deep sequencing. In contrast to the gRNA target sites in exon 1
and exon 6 of the F9 gene (Table 2), we found no evidence of genome
editing in these putative off-target sites (detection limit of Illumina
deep sequencing—0.095%)58 when the truncated gRNAs are em-
ployed, as in the case of full-length gRNAs. This further supports
the speciﬁcity of the truncated gRNAs. Fu et al.34 have also shown
that not all truncated gRNAs have improved speciﬁcity comparedMolecular Therapy Vol. 26 No 5 May 2018 1249
Molecular Therapyto full-length gRNAs. Additionally, they showed that some of the
tested gRNAs have no detectable off-target effects for both full-length
and truncated gRNAs, consistent with our results. Hence, the impact
of truncated gRNAs on targeting efﬁciency and speciﬁcity cannot be
generalized and would need to be tested on a case-by-case basis.
Nevertheless, there is still a need to further reﬁne the computational
algorithms for prediction of off-target sites. Alternatively, a compre-
hensive assessment of off-target sites based on sensitive in vivo detec-
tion assays would need to be developed. This is challenging and is
beyond the scope of the current study. This could potentially be
accomplished using an adaptation of the GUIDE-seq approach,59
which relies on the capture of double-stranded oligonucleotides
into dsDNA breaks. Alternatively, integration-defective lentiviral vec-
tors could be employed.38,60
The current CRISPR/Cas9-based approach offers new opportunities
to achieve rapid, efﬁcient, and speciﬁc genome targeting in liver
and may facilitate functional genomics studies without necessarily
having to rely on transgenic mouse models. The generation of trans-
genic mice is time consuming and costly, especially if it requires com-
plex breeding schemes to combine mutations in different genes. The
current validation of an efﬁcient and speciﬁc CRISPR/Cas9-mediated
in vivo targeting strategy in hepatocytes may facilitate and expedite
the creation of complex disease models by inactivating multiple genes
based on gRNA multiplexing.1,61,62 Ultimately, this versatile and
improved CRISPR/Cas9-based system has potentially broad implica-
tions for the ﬁeld and may pave the way toward the treatment of
genetic, acquired, or infectious liver diseases by either NHEJ or
HDR.2,6,21,23,24,27,63,64
MATERIALS AND METHODS
Construction of CRISPR/Cas9 AAV Vectors
The Streptococcus pyogenesCas9 (no. 41815; Addgene)4 was cloned in
single-stranded AAV vector AAVss-HS-CRM8-TTRmin-MCS-
SV40polyA35 at XbaI/AgeI restriction sites, which was subsequently
conﬁrmed by Sanger sequencing. The DNAs corresponding to the
selected truncated gRNAs that target exon 1 and exon 6 of the
mouse F9 gene (i.e., mF9 Exon 1: GCACCTGAACACCGTCA; mF9
Exon 6: GACTTCACTCGAGTTGT) and the scrambled control
(GGGTCTTCGAGAAGACCT) were cloned into a gRNA cloning vec-
tor (no. 41824; Addgene).4 The scrambled gRNA is identical, as pre-
viously described by Anderson and colleagues27 and was used as a
negative control gRNA. Brieﬂy, the gRNA cloning vector was linear-
ized using AﬂII restriction enzyme. The oligos were designed, an-
nealed, and extended using Phusion Hot Start II high-ﬁdelity DNA
polymerase (F549S; Life Technologies), according to the supplier’s in-
structions. These 100-bp oligos were subsequently cloned into the
AﬂII-linearized gRNA cloning vector. The resulting vector was then
digested by XhoI/NotI, and the fragment was then cloned into the
corresponding site of the AAV vector designated as AAVss-HS-
CRM8-TTRmin-MCS-SV40polyA,35 which was sequence veriﬁed.
The oligos used for cloning of the mF9 targeting gRNAs were as
follows: U6-mF9-Exon1-gRNA (targets exon 1 of the mouse F9 gene):1250 Molecular Therapy Vol. 26 No 5 May 201850-TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACAC
CGCACCTGAACACCGTCA-30, 50-GACTAGCCTTATTTTAAC
TTGCATTTCTAGCTCTAAAACTGACGGTGTTCAGGTGC-30;








The ﬁnal scrambled control plasmid obtained from above steps was
then used as the vector backbone to generate the full-length gRNAs
that target exon 1 (i.e.,mF9 Exon 1:GAAGCACCTGAACACCGTCA).
A fragment ﬂanked with NdeI/XbaI containing this 20-nt gRNA
sequence was generated (Geneart; Life Technologies, Europe) and
cloned using the same restriction sites in the scrambled gRNA control
plasmid.Vector Production and Purification
To produce the AAV serotype 9 vectors, AAV-293 cells were cotrans-
fected using calcium phosphate (Invitrogen, Carlsbad, CA, USA) with
the AAV plasmid of interest, a chimeric packaging construct, and an
adenoviral helper plasmid, as described previously.33 Cells were har-
vested two days post-transfection and lysed by successive freeze/thaw
cycles and sonication, followed by Benzonase (Novagen, Madison,
WI, USA) and deoxycholic acid (Sigma Aldrich, St. Louis, MO,
USA) treatments and 3 consecutive rounds of cesium chloride (Invi-
trogen, Carlsbad, CA, USA) density gradient ultracentrifugation.
Fractions containing the AAV vector particles were collected and dia-
lyzed in Dulbecco’s PBS (GIBCO, BRL) containing 1 mM MgCl2.
Quantitative real-time PCR with SYBR Green and primers for the
HS-CRM8-TTRmin (Cas9 vector) or U6 promoter (gRNAs) were
used to determine vector titers. The HS-CRM8-TTRmin forward
primer sequence was 50-GGAGGCTGCTGGTGAATATT-30 and the
reverse primer sequence was 50- TCCAAACCTGCTGATTCTG-30.
The U6 forward primer sequence was 50-GCAGGCTTTAAAGGAAC
CAA-30 and the reverse primer sequence was 50- ACTGCAAACT
ACCCAAGAAAT-30. To generate the standard curves, known copy
numbers of the corresponding vector plasmids were used.Animals
The animal experiments were approved by the University’s Animal
Ethics Committee. C57BL/6 mice (Taconic, Denmark; Janvier Labs,
France) were used in this study. One- to 2-day-old neonatal mice
were injected into the facial vein with two different doses of the
AAV9-HS-CRM8-TTRmin-Cas9 vector (i.e., 6.25  1010 vg/mouse
or 1.25  1011 vg/mouse i.v.) and AAV9-U6-mF9-Exon1-gRNA20,
AAV9-U6-mF9-Exon1-gRNA17, AAV9-U6-mF9-Exon6-gRNA17,
or control AAV9-U6-scrambled-gRNA (i.e., 1.25  1011 vg/mouse
or 2.5  1011 vg/mouse i.v.). The ratio of Cas9 to gRNA vectors
was kept constant (i.e., 1:2) at both vector doses.65
www.moleculartherapy.orgAlso, 4-week-old mice were injected into tail vein with AAV9-HS-
CRM8-TTRmin-Cas9 vector (1.25  1011 vg/mouse i.v.) and
AAV9-U6-mF9-Exon1-gRNA20, AAV9-U6-mF9-Exon1-gRNA17,
or control AAV9-U6-scrambled-gRNA (2.5  1011 vg/mouse
i.v.). The ratio of Cas9 to gRNA vectors was kept constant (i.e.,
1:2).
To obtain plasma samples, whole blood was collected at regular
intervals into buffered citrate, followed by centrifugation at 4C,
13,000 rpm for 4 min. To obtain serum samples, blood was collected
by phlebotomy of the retro-orbital plexus using non-heparinized cap-
illaries and allowed to clot for 1 or 2 hr, followed by centrifugation.
FIX activity was determined in plasma using a Factor IX chromogenic
assay (BIOPHEN, Hyphen BioMed, France), according to the manu-
facturer’s protocol. For the standard curve, plasma from age-matched
non-injected C57BL/6 mice was used. AST and ALT activity was
determined in serum using AST (MAK055-1KT, Sigma-Aldrich,
MO, USA) and ALT activity assay kits (MAK052-1KT, Sigma-Al-
drich, MO, USA), according to the manufacturer’s protocol. The
cytokine levels were measured using the Mouse Inﬂammatory Cyto-
kines Multi-Analyte ELISA Array (MEM-004A, QIAGEN Benelux
B.V, Belgium), according to manufacturer’s protocol. The anti-Cas9
antibody levels were analyzed using a modiﬁed ELISA protocol.25,66
Brieﬂy, ninety-six-well Nunc ﬂat-bottom plates (Thermo Scientiﬁc)
were coated with the SpCas9 protein (0.5 mg/well; PNA Bio; cat no.
CP01) in 1 coating buffer (Coating Solution Concentrate Kit;
KPL) overnight at 4C. The plates were then washed with 1 wash
buffer diluted from 20 Wash Solution (KPL) and blocked with
1% BSA Blocking Solution (KPL) for 1 hr at room temperature.
Mouse plasma was diluted 40-fold with 1% BSA Diluent Solution
(KPL), added to the wells, and incubated for 1 hr at room temperature
with shaking (200 rpm). The mouse monoclonal antibody against
SpCas9 (Epigentek; clone 7A9; cat no. A-9000-100) was serially
diluted and used as a standard to quantify immunoglobulin G1
(IgG1). After washing, each well was incubated with 100 mL of horse-
radish peroxidase (HRP)-labeled goat anti-mouse IgG1 (Santa Cruz
Biotechnology; diluted 1:4,000) for 1 hr at room temperature. The
wells were washed four times and incubated with 100 mL of ABTS
ELISAHRP Substrate (KPL). Optical density at 410 nmwasmeasured
using a microplate reader. The IgG1 standard curve was generated us-
ing the four-parameter logistic regression equation (4PL). Bleeding
time was assessed using a tail-clip assay. Brieﬂy, mice were anesthe-
tized and the tail was placed in pre-warmed 37C normal saline solu-
tion for 2 min and subsequently cut at 2 or 3 mm diameter. The tail
was then immediately placed in 37C saline solution, and mice were
monitored to assess the bleeding time.
Biodistribution and Copy Number Analysis
Genomic DNA was extracted from different tissues using the DNeasy
Blood and Tissue Kit (QIAGEN, Chatsworth, CA, USA). 100 ng DNA
was analyzed using qPCR ABI Prism 7900HT (Applied Biosystems,
Foster City, CA, USA) with HS-CRM8-TTR-speciﬁc primers 50-GG
AGGCTGCTGGTGAATATT-30 (forward) and 50-TCCAAACCTGC
TGATTCTG-30 (reverse). To generate standard curves, known copynumbers of the corresponding vector plasmid was used. The
mRNA was isolated from different organs using a NucleoSpin RNA
extraction kit (Machery-Nagel, Germany). Using a cDNA synthesis
kit (Invitrogen, Carlsbad, CA, USA), 250 ng of RNA from each organ
was reverse transcribed to cDNA. cDNA was then analyzed by qPCR
ABI Prism 7900HT (Applied Biosystems, Foster City, CA, USA) us-
ing Cas9-speciﬁc primers 50-GTGCCCCAGTCTTTTCTCA-30 (for-
ward) and 50-CAACTCAGACAGGCCACCT-30 (reverse). The expres-
sion levels were normalized to murine glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA expression, obtained by using the
forward primer 50-TGTGTCCGTCGTGGATCTGA-30 and reverse
primer 50-GCCTGCTTCACCACCTTCTTGA-30. Cas9 expression
levels based on the 2-DCT method were determined in the organs of
mice injected with AAV9-HS-CRM8-TTRmin-Cas9 vector (6.25 
1010 vg/mouse i.v.) and AAV9-U6-mF9-Exon120 gRNA (i.e., 1.25 
1011 vg/mouse i.v.).
T7E1-Based Enzyme Mismatch Cleavage Assay
PCR reactions were performed using Phusion Hot Start II high-
ﬁdelityDNApolymerase (F549S; Life Technologies), using the respec-
tive PCR primers and conditions (see below and Table S3). For the
T7E1 assay on the target site of mF9-Exon1-gRNA, primers T7E1-
mF9-Exon1-F/R and Nested2-T7E1-Exon1-F/R were used, and for
the T7E1 assay on the target site of mF9-Exon6-gRNA, primers
T7E1-Ex6-Pair2-mF9-F/R and Nested6Ex6Pair2F/R were used. All
tested loci ampliﬁed successfully using nested PCR. PCR products
were analyzed on a 3% agarose gel to verify both size and purity and
were run with a DNAmarker (SM0331; Fermentas) for size reference.
The PCR products were subjected to denaturation and reannealing us-
ing a S1000 thermocycler (Bio-Rad). The cycle conditions used for
denaturation and reannealing were 95C for 2 min, ramp at 2C per
second until 85C was reached followed by 85C for 2 min, ramp at
0.1C per second until 25C (Table S3), 25C for 2 min, and then
kept at 16C until used for T7E1 digestion. T7E1 digestion was done
at 37C for 20 min, along with undigested controls. The resulting
products were run on 3% agarose gel to observe evidence for indels.
Genome editing efﬁciencies were determined by densitometric quan-
tiﬁcation of the gel bands using NIH ImageJ 1.49.
DNA Sequencing of CRISPR/Cas9-Induced Indel Mutations
The nested PCR products obtained by the T7E1 assay were ﬁrst
subjected to Sanger sequencing. PCR products were puriﬁed using
ExoSAP-IT (78250; Affymatrix) and were cloned into Zero Blunt
TOPO vector (K2875-J10; Life Technologies). The plasmid DNAs
were isolated using pureyield plasmid miniprep system (A1222;
Promega). Plasmids were sequenced using an M13 forward primer
(50-GTAAAACGACGGCCAG-30) by the Sanger sequencing method
(GATC, Germany). Subsequently, the gRNA target sites in the F9
gene and their respective predicted top three off-target sites (Tables
S1 and S2), as predicted by the algorithm from the Zhang lab
(http://crispr.mit.edu/) were subjected to deep sequencing. Brieﬂy,
the PCRs were done at the mF9-Exon1-gRNA and mF9-Exon6-
gRNA target sites and the predicted top three off-target sites, using
the respective primers (Table S4). PCR reactions were done usingMolecular Therapy Vol. 26 No 5 May 2018 1251
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Life Technologies) to generate PCR products of size 200–230 bp.
The PCR products were puriﬁed by QIAquick PCR Puriﬁcation
Kit (catalog no. 28104; QIAGEN). The resulting PCR products
were sequenced and analyzed using the MiSeq PE150 platform
(BGI, Europe). Raw image ﬁles were processed by Illumina
pipeline for base calling with default parameters, and the sequences
of each individual were generated as 150-bp paired-end reads.
The 150-bp paired-end reads were subjected to bioinformatics
analysis.
Bioinformatics Analysis of Deep Sequencing Data
The bioinformatics analysis began from the sequencing data (raw
data), which were generated from the Illumina pipeline. First, the
adaptor sequence in the raw data was removed, and low quality
reads that have too many undeﬁned nucleotides or low base qual-
ity were discarded. This step produced the “clean data”. Second,
Burrows-Wheeler Aligner (BWA) was used to do the alignment.
BWA gave the result in BAM format ﬁles. The BAM format ﬁles
were further processed, such as ﬁxing mate information of the
alignment, adding read group information and removing duplicate
reads caused by PCR. For qualitative analysis, we used IGV 2.3.59
for viewing BAM ﬁles aligned at on-target and off-target sites with
mouse reference genome (mm10). The indels were considered to
be caused due to the gRNA, if they were localized within 10 bp
of its expected cut site. This cut site was assumed to be around
3 bp upstream of the CRISPR/Cas9 PAM sequence. For quantita-
tive analysis of BAM ﬁles, we used the web-interface-based cloud
computing platform Biostar Galaxy (https://usegalaxy.org).50 The
web interface of galaxy could be used to run command-line-driven
tools, such as samtools. The individual target sequences were made
as BED ﬁles, which contained the chromosomal positions of tar-
geted sites. The BED ﬁles were used for alignment with BAM ﬁles
to recognize presence of indels. The BED ﬁles and BAM ﬁles were
uploaded to the server of https://usegalaxy.org to perform the
analysis. Then, “mpileup” under NGS:samtools was run on each
BAM ﬁle to calculate the percentage of indels, with mouse (Mus
musculus): mm10 assembly as reference genome. Genotype likeli-
hood computation was performed with vcf. as output format. The
vcf. ﬁlter was applied to the vcf. dataset generated using mpileup to
create the dataset containing indels. The parameters used for anal-
ysis of indels can be found at https://usegalaxy.org/u/ksingh/w/
copy-of-indel-analysis-workﬂow-constructed-from-history-mf9-
analysis. These vcf. datasets provided indels, if any, at the targeted
site along with the maximum fraction of reads supporting an indel
(IMF; i.e., maximum fraction of reads supporting an indel). The
IMF values were multiplied by 100 to get the maximum percentage
of reads supporting an indel.
Statistics
To analyze data, Microsoft Excel Statistics package was used. Values
shown in the ﬁgures are mean ± SD. Statistical signiﬁcance was deter-
mined using Student’s t test. For kinetic studies, statistics were per-
formed using a repeated-measure two-way ANOVA.1252 Molecular Therapy Vol. 26 No 5 May 2018SUPPLEMENTAL INFORMATION
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